Piper Jaffray HC Conference...Just listened to the webcast and no mention of Urocidin. On a different but related note, the following Piper Jaffray summary might be of interest, if not aware.
A quick update from Piper Jaffray (back in March, 2011), re Urocidin trial results... and the title pretty well sums up the summary:
Endo: Urocidin (Phase III/Bladder Cancer)
Interim Data Encouraging; Sales Potential of ~$110M Reasonablehttps://www.healthace.com/rssfeed/Oncology_Report_032111M.pdf(see page 5)
The assumptions used by Piper Jaffray, for the $110 miilion in sales potential for Urocidin, are quite different from what Taylor Collison used in their Feb 4-11 report (see TC's page 29).
TC's calculation for Urocidin sales, in the U.S market, hit $102 million (gross$) in year 2 or 2016. Then, growing to $310 million by 2021 (just U.S. market)
Nevertheless, very large numbers (from Piper Jaffray or TC) from the perspective of Bioniche. Plus, the descriptive "encouraging" used by Piper Jaffray in March re trial results, was positive. And, the related transfer/manufacturing revenue numbers back to Bioniche, puts the company into a different league. In year 2, $16.5 million just for the U.S market, according to TC.
The market should have already assigned a value for the above back to Bioniche (to a degree)*. An awareness issue for sure. And, for those marginally aware and taking a wait-and-see" approach, a "tipping point" will come. Looking forward to BNC to do something more to help with that tip and also build awareness.
*Tania's thesis (October-11): The current market valuation for BNC ignores both the Human Health Division containing a partnered Phase III development product,and the Food Safety Division with a commissioned, state-of-the-art vaccine manufacturing facility having annual capacity of over 40M doses/year. (per Bail's post of Oct.28-11)
rg